

RECEIVED
CENTRAL FAX CENTER

MAR 17 2005

Lilly

Fax Cover Sheet

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A.

LRLLaw

To: Central Facsimile From: Thomas E. LaGrandeur
Eli Lilly And Company

Company: USPTO 317/ 276-3681

Fax: 703.872.9306 Phone: (317) 651-1527

Phone: _____ Total Pages (including cover): 31

Date: March 17, 2005

RE: Response Under 37.C.F.R. 111 & Amendment Under 37
C.F.R. 1.121

Serial No.: 10/602,936

Our Ref.: X-12448B US

Faxed herewith is the response to the Office Action mailed November 17, 2004 for the above-referenced application.

Also included are the following documents:

1. Fee Transmittal
2. Exhibit A – Letter to the Editor
3. Exhibit B – Activated protein C versus protein C in severe sepsis
4. Exhibit C - Improved Survival with Plasma Exchange in Patients With Thrombotic Thrombocytopenic Purpura- Hemolytic Uremic Syndrome

Answers That Matter.

RECEIVED
CENTRAL FAX CENTER

MAR 17 2005

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Ethel Gaines
Type or print name of person signing certification
Ethel Gaines March 17, 2005
Signature Date

**PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: FISHER Charles Jack

Group Art Unit:

Serial No.: 10/602936

1653

Filed: June 24, 2003

Examiner:

Holly Schnizer

For: METHOD OF TREATING

THROMBOCYTOPENIC PURPURA AND
HEMOLYTIC UREMIC SYNDROME

Docket No.: X12448B

RESPONSE UNDER 37 C.F.R. 1.11 & AMENDMENT UNDER 37 C.F.R. 1.121

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Introductory Comments

This response is submitted in reply to the Office Action mailed November 17, 2004 for the above-referenced application.

Enclosed is a petition for a one-month extension of time under 37 C.F.R. § 1.136. The Applicants authorize the Office to charge the necessary fee for an extension of time to Deposit Account No. 05.0640 in the name of Eli Lilly and Company.

Please amend the application as follows:

Amendments to the Claims are reflected in the listing of the claims which begins on page 2 of this paper.

Remarks begin on page 5 of this paper.